Here at PAM Theragnostics we are passionate about the development of therapeutic and diagnostic tools for diseases associated with maturation of amidated peptide hormones. With more than 50 million people worldwide suffering from the “modern world plague”, the Alzheimer disease (AD), the onset of which is linked to the amount of amidated peptide hormones, we make it our goal to develop an easy and reliable tool for early diagnosis of AD. Our target is peptidylglycine α-amidating monooxygenase (PAM), the only enzyme known to catalyze the reaction of α-amidation, the final step in peptide hormones activation. Our long-term vision is to provide safe and cost-effective therapy for the Alzheimer patients.
Andreas Bergmann, Ph. D. | Chief Executive Officer
Dr. Andreas Bergmann is a visioner, who has launched and co-founded several successful biotech companies, including sphingotec GmbH, 4TEEN4, Adrenomed AG. Holding an outstanding track record of over 180 peer-reviewed scientific publications and 204 patent rights, he dedicated his life to development of blood-based diagnostic methods for prediction, prevention, intervention strategies and early treatment of cardiovascular diseases, cancer and acute care fields.
- Paul Kaufmann | R&D scientist
- Yulia Ilina, Ph.D. | R&D scientist
- Michaela Press | R&D scientist
- Katrin Thüne, Ph.D | R&D scientist
PAM Theragnostics GmbH
WE ARE HIRING!
Are you a highly motivated team player and a self-starter with a great work ethic? Great, our company is looking for the individuals exactly like you. If you are interested in joining our team, please contact us at firstname.lastname@example.org